Low-dose naltrexone and NAD+ for the treatment of patients with persistent fatigue symptoms after COVID-19

Anar Isman,a Andy Nyquist,a,∗ Bailey Strecker,a et. al., Brain Behav Immun Health. 2024 Mar; 36: 100733. doi: 10.1016/j.bbih.2024.100733PMCID: PMC1086240, PMID: 38352659 Abstract A subset of patients experiences persistent fatigue symptoms after COVID-19, and patients may develop long COVID,…[...]

Read More

Safety and efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study.

O'Kelly B 1,2, Vidal L 2, McHugh T 2, et. al. Brain, Behavior, & Immunity - Health, 03 Jul 2022, 24:100485, https://doi.org/10.1016/j.bbih.2022.100485 PMID: 35814187 PMCID: PMC9250701 Abstract  Background Up to 37.7% of patients experience symptoms beyond 12 weeks after…[...]

Read More